AXSM – Axsome Therapeutics, Inc.

AXSM — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.36

Margin Of Safety %

Put/Call OI Ratio

1.01

EPS Next Q Diff

0.92

EPS Last/This Y

1.97

EPS This/Next Y

7.59

Price

235.92

Target Price

270.89

Analyst Recom

1.24

Performance Q

35.03

Upside

-155.5%

Beta

0.6

Ticker: AXSM

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-24	AXSM	186.2	0.71	2.39	25604
2026-04-27	AXSM	187.32	0.72	7.29	25932
2026-04-28	AXSM	185.04	0.81	0.44	27653
2026-04-29	AXSM	183.99	0.80	0.34	27952
2026-04-30	AXSM	207.56	0.79	1.17	28275
2026-05-01	AXSM	206.35	0.66	5.13	27596
2026-05-04	AXSM	223.33	0.94	0.36	33136
2026-05-05	AXSM	223.03	0.92	0.45	34505
2026-05-06	AXSM	222.62	0.94	0.14	35185
2026-05-07	AXSM	219.06	0.92	0.62	35575
2026-05-08	AXSM	217.28	0.94	0.66	35869
2026-05-11	AXSM	216.24	0.95	0.36	36255
2026-05-12	AXSM	223.86	0.96	0.37	36704
2026-05-13	AXSM	235.46	0.93	0.16	37920
2026-05-14	AXSM	232.23	0.93	0.12	38097
2026-05-15	AXSM	227.77	0.93	0.40	38333
2026-05-18	AXSM	227.19	1.06	0.09	26609
2026-05-19	AXSM	226.78	1.03	0.52	27451
2026-05-20	AXSM	230.39	1.03	0.30	27702
2026-05-21	AXSM	233.52	1.06	0.10	27928
2026-05-22	AXSM	235.96	1.01	0.11	29131
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-24	AXSM	185.69	38.1	241.4	-1.01
2026-04-27	AXSM	187.32	38.1	242.0	-1.01
2026-04-28	AXSM	185.04	37.8	241.5	-1.23
2026-04-30	AXSM	207.98	37.8	249.6	-1.23
2026-05-01	AXSM	206.72	32.0	249.2	-1.26
2026-05-04	AXSM	223.31	32.0	255.0	-1.26
2026-05-05	AXSM	223.02	29.4	254.9	-1.21
2026-05-06	AXSM	222.80	29.4	255.1	-1.21
2026-05-07	AXSM	220.21	17.1	-	-2.29
2026-05-08	AXSM	217.47	17.1	-	-2.29
2026-05-11	AXSM	216.40	15.7	-	-1.70
2026-05-12	AXSM	223.98	15.7	-	-1.71
2026-05-13	AXSM	235.23	15.7	-	-1.71
2026-05-14	AXSM	232.23	15.7	-	-1.71
2026-05-15	AXSM	227.64	15.7	-	-1.71
2026-05-18	AXSM	227.35	15.7	-	-1.71
2026-05-19	AXSM	226.75	15.7	-	-1.71
2026-05-20	AXSM	230.56	15.7	-	-1.71
2026-05-21	AXSM	233.55	15.7	-	-1.71
2026-05-22	AXSM	235.92	15.7	-	-1.71
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-24	AXSM	-6.19	-0.15	6.59
2026-04-27	AXSM	-6.19	0.09	6.23
2026-04-28	AXSM	-6.19	0.09	6.23
2026-04-29	AXSM	-6.19	0.09	6.23
2026-04-30	AXSM	-6.19	0.09	6.23
2026-05-01	AXSM	-6.19	0.09	6.23
2026-05-04	AXSM	-6.19	-0.02	6.23
2026-05-05	AXSM	-6.19	-0.02	6.23
2026-05-06	AXSM	-4.45	-0.02	6.23
2026-05-07	AXSM	-4.42	-0.02	6.20
2026-05-08	AXSM	-4.42	-0.02	6.20
2026-05-11	AXSM	-4.42	0.19	6.20
2026-05-12	AXSM	-4.42	0.19	6.36
2026-05-13	AXSM	-4.42	0.19	6.36
2026-05-14	AXSM	-4.42	0.19	6.36
2026-05-15	AXSM	-4.42	0.19	6.36
2026-05-18	AXSM	-4.42	-1.15	6.36
2026-05-19	AXSM	-4.43	-1.15	6.36
2026-05-20	AXSM	-4.43	-1.15	6.36
2026-05-21	AXSM	-4.43	-1.15	6.36
2026-05-22	AXSM	-4.43	-1.15	6.36
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.26

Avg. EPS Est. Current Quarter

-0.82

Avg. EPS Est. Next Quarter

-0.34

Insider Transactions

-4.43

Institutional Transactions

-1.15

Beta

0.6

Average Sales Estimate Current Quarter

222

Average Sales Estimate Next Quarter

262

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-72.9

Target Price

270.89

P/E

Forward P/E

40.83

PEG

P/S

17.15

P/B

222.28

P/Free Cash Flow

EPS

-3.74

Average EPS Est. Cur. Y

-1.71

EPS Next Y. (Est.)

5.89

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.59

Relative Volume

0.82

Return on Equity vs Sector %

-372

Return on Equity vs Industry %

-356.4

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.66

EBIT Estimation

◆ AXSM Healthcare

$235.97

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

6/25

Volume

7/15

Valuation

7/20

TP/AR

6/10

Options

4/10

RSI

73.4

Range 1M

99.6%

Sup Dist

3.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

19/30

Estimates

6/20

Inst/Vol

4/15

Options

4/10

EPS Yr

46.7%

EPS NY

394.6%

52W%

99.8%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -4.8% upside

Quality

6/30

Valuation

0/30

Growth

16/25

Stability

1/10

LT Trend

4/5

Upside

-4.8%

Quality

Axsome Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1220

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

AXSM

Latest News

—

Caricamento notizie per AXSM…

stock quote shares AXSM – Axsome Therapeutics, Inc. Stock Price stock today

news today AXSM – Axsome Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AXSM – Axsome Therapeutics, Inc. yahoo finance google finance

stock history AXSM – Axsome Therapeutics, Inc. invest stock market

stock prices AXSM premarket after hours

ticker AXSM fair value insiders trading

AXSM – Axsome Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AXSM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y